Detail akcie BioArctic-B Rg online

Business Summary: BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, BioArctic AB revenues increased from SEK156.1M to SEK1.82B. Net income applicable to common stockholders totaled SEK1.03B vs. loss of SEK145.6M. Revenues reflect Milestone Payments segment increase from SEK0K to SEK1.41B, Royalties segment increase from SEK133.7M to SEK375.6M, North America segment increase from SEK89.8M to SEK1.25B, Asia segment increase from SEK57.7M to SEK540.8M.